What Is a 21-Day R-CHOP Cycle Like for DLBCL Patients?
At a Glance
A 21-day R-CHOP cycle typically starts with four IV medicines on Day 1 and prednisone through Day 5, reaches its hardest period around Days 6–14 as infection risk and fatigue peak, and allows blood count recovery in Days 15–21 before the next CBC-guided cycle.
A standard 21-day cycle of R-CHOP chemotherapy follows a general rhythm, though every person’s body reacts differently. R-CHOP is a combination regimen that includes intravenous (IV) infusions of Rituximab, Cyclophosphamide, doxorubicin (also known as Hydroxydaunorubicin), and vincristine (Oncovin), plus oral Prednisone [1][2].
Generally, Days 1 to 5 involve the immediate effects of the infusions and the activating side effects of oral steroids [1]. Days 6 to 14 are typically the hardest part of the cycle, characterized by peak fatigue and your immune system reaching its lowest point (the “nadir”) [3][4]. Finally, Days 15 to 21 offer a potential period of recovery where blood counts begin to rise before the next cycle [4].
Understanding this rough timeline can help you plan your life, but remember that symptoms can accumulate over multiple cycles, and your exact timeline may vary.
⚠️ URGENT: When to Call Your Care Team
During chemotherapy, a fever is considered a medical emergency. Do not wait for your next appointment or wait until morning. Many oncology teams instruct patients to call their 24-hour number immediately for a temperature of 100.4°F (38.0°C) or higher, or if you experience chills and feel unwell even without a fever [3][5]. Seek urgent medical care if you experience shortness of breath, confusion, severe weakness, or uncontrolled vomiting.
Days 1 to 5: Treatment and Steroid Effects
Your cycle begins on Day 1 with IV infusions of the four chemotherapy and immunotherapy drugs [1][2]. You will also start taking a high dose of oral prednisone on Day 1, which typically continues through Day 5.
- Infusion Reactions: During your IV treatment, especially the rituximab infusion, you are closely monitored. Alert your infusion nurse immediately if you feel chills, flushing, rash, chest or throat tightness, shortness of breath, or dizziness.
- Steroid Effects: Prednisone can cause insomnia, restlessness, mood changes, indigestion, and elevated blood sugar [1]. If you have diabetes or experience severe anxiety or mood shifts, contact your care team.
- Digestive Changes: Nausea and constipation are common early in the cycle [6]. Constipation is often driven by the drug vincristine combined with anti-nausea medications [6]. Do not start laxatives on your own; ask your team for an approved bowel regimen. Call your clinic if you go several days without a bowel movement or have severe abdominal pain.
Days 6 to 14: The “Nadir” and Infection Risk
After the steroids end, you may notice a drop in energy or mood. As you move into the second week, the chemotherapy reaches its maximum effect on your bone marrow, causing your blood counts to drop.
This period is known as the nadir—the lowest point for specific blood cell lines. Your white blood cells (neutrophils), which fight bacteria, will deplete, leading to neutropenia [6][3].
- High Infection Risk: Because of low neutrophils, your body cannot fight off infections easily [3]. Research shows that the very first cycle of R-CHOP carries a particularly high risk for developing fever with low white counts (febrile neutropenia), so vigilance is critical from the start [7].
- Fatigue: Fatigue during this time is multifactorial—caused by the lymphoma itself, steroid withdrawal, poor sleep, and the direct effects of the treatment [8]. Over multiple cycles, cumulative red blood cell drops (anemia) can also worsen fatigue.
- Other Side Effects: You may develop mouth sores (mucositis) that make eating difficult [3]. You might also notice bruising or bleeding if your platelet counts drop, or tingling in your fingers and toes (neuropathy) from the vincristine.
Growth Factor Injections: To reduce the duration and severity of neutropenia, your doctor may prescribe a white blood cell booster (a G-CSF drug like pegfilgrastim). This is typically given 24 to 72 hours after chemotherapy [9][10]. While it lowers the risk of severe infection, it does not prevent all infections and can cause bone or muscle pain.
Days 15 to 21: Count Recovery
By the third week, your bone marrow usually begins to recover. Your blood counts will gradually rise back toward safer levels, and many patients feel a physical and mental improvement [4].
However, you are not automatically “safe” just because it is the third week. Before starting your next 21-day cycle, your care team will check your Complete Blood Count (CBC). The next cycle will only proceed if your blood test confirms your counts have safely recovered. If they are still too low, your doctor may delay your next treatment by a few days to give your bone marrow more time to heal.
Common questions in this guide
What happens during the first five days of a 21-day R-CHOP cycle?
When is the nadir during R-CHOP, and why does it matter?
What fever should I report during R-CHOP chemotherapy?
Will I receive pegfilgrastim during an R-CHOP cycle?
Can the next R-CHOP cycle start if my blood counts are still low?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific temperature reading should prompt an immediate call to the after-hours number, and what is that phone number?
- 2.What is your recommended bowel regimen to prevent constipation from vincristine and anti-nausea medications?
- 3.Will I receive a white blood cell growth factor (like pegfilgrastim), and how will it be administered?
- 4.What should I do if I experience severe mood changes or blood sugar spikes while taking the oral steroids?
- 5.Are there specific food safety precautions I need to follow, or do I need to be on a specialized diet during my low-count days?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (10)
- 1
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
Offner F, Samoilova O, Osmanov E, et al.
Blood 2015; (126(16)):1893-901 doi:10.1182/blood-2015-03-632430.
PMID: 26232170 - 2
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A, Cummin TE, Barrans S, et al.
The Lancet. Oncology 2019; (20(5)):649-662 doi:10.1016/S1470-2045(18)30935-5.
PMID: 30948276 - 3
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL, Wilson WH, Jung SH, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(21)):1790-1799 doi:10.1200/JCO.18.01994.
PMID: 30939090 - 4
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, et al.
Lancet (London, England) 2019; (394(10216)):2271-2281 doi:10.1016/S0140-6736(19)33008-9.
PMID: 31868632 - 5
Risk Factors for Febrile Neutropenia in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Undergoing Initial R-CHOP Treatment.
Chen LY, Tsai CA, Liao PW, et al.
Clinical Medicine Insights. Oncology 2026; (20()):11795549261423995 doi:10.1177/11795549261423995.
PMID: 41727336 - 6
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U, Trněný M, Belada D, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(31)):3529-3537 doi:10.1200/JCO.2017.73.3402.
PMID: 28796588 - 7
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
Morrison VA, Weller EA, Habermann TM, et al.
Leukemia & lymphoma 2017; (58(8)):1814-1822 doi:10.1080/10428194.2016.1265111.
PMID: 27967294 - 8
Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients.
Watson C, Barlev A, Worrall J, et al.
Journal of drug assessment 2020; (10(1)):18-26 doi:10.1080/21556660.2020.1854561.
PMID: 33489434 - 9
Effects of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis for chemotherapy-induced febrile neutropenia in diffuse large B-cell lymphoma patients receiving the R-CHOP-21 regimen.
Nakaphan P, Uaprasert N
Asian biomedicine : research, reviews and news 2025; (19(4)):165-173 doi:10.2478/abm-2025-0021.
PMID: 40904615 - 10
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB, LaPlant B, McPhail E, et al.
The Lancet. Haematology 2016; (3(7)):e309-16.
PMID: 27374464
This page is for informational purposes only and does not constitute medical advice. Your oncology team should tailor R-CHOP instructions to your situation, especially if you develop a fever or other urgent symptoms.
Get notified when new evidence is published on Diffuse large B-cell lymphoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.